Form 4: Luke Evnin Sells Werewolf Therapeutics Shares

Director Luke Evnin reported a sale of 44,679 shares of Werewolf Therapeutics common stock for approximately $0.54 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Luke Evnin, a Director at Werewolf Therapeutics, Inc. (HOWL), reported a transaction on May 13, 2026.
• The transaction involved the sale of 44,679 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan established on March 26, 2026.
• The reported sale price was a weighted average of $0.54 per share, with individual transactions ranging from $0.5077 to $0.61.
• Following the sale, Evnin beneficially owns 1,126,496 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although the use of a Rule 10b5-1 plan mitigates strong negative sentiment.

Negatives

• Director Luke Evnin sold a significant number of shares (44,679) of common stock.
• The sale occurred at a weighted average price of $0.54 per share, indicating a potentially low valuation or market sentiment at the time of sale.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The sale by a director under a Rule 10b5-1 plan suggests a pre-determined selling strategy, often used to diversify holdings or manage personal finances without implying negative sentiment about the company's future prospects.

Stakeholder Impact

• Shareholders may view the sale by a director with caution, although the Rule 10b5-1 plan indicates a pre-arranged strategy.
• The sale does not directly impact employees, customers, suppliers, or creditors based on the information provided.

Key Dates

Keywords

Form 4, Insider Trading, Werewolf Therapeutics, HOWL, Luke Evnin, Rule 10b5-1, Stock Sale, Beneficial Ownership